Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)

Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9, an extracellular enzyme involved in matrix remodeling, tumor growth, and metastases. A phase I and Ib study of modified oxaliplatin, leucovorin, and fluorouracil (mFOLFOX6) with ADX revealed encouraging antitumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Manish A., Bodoky, Gyorgy, Starodub, Alexander, Cunningham, David, Yip, Desmond, Wainberg, Zev A., Bendell, Johanna, Thai, Dung, He, Joyce, Bhargava, Pankaj, Ajani, Jaffer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078292/
https://www.ncbi.nlm.nih.gov/pubmed/33577358
http://dx.doi.org/10.1200/JCO.20.02755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078292/
https://www.ncbi.nlm.nih.gov/pubmed/33577358
http://dx.doi.org/10.1200/JCO.20.02755

Ejemplares similares